BMJ 2002;325:633-634 ( 21 September )

Papers

Accumulation of prion protein in tonsil and appendix: review of tissue samples

David A Hilton, neuropathologist aAzra C Ghani, research fellow bLisa Conyers, research technician aPhilip Edwards, biomedical scientist aLinda McCardle, biomedical scientist cMark Penney, research technician aDiane Ritchie, research assistant cJames W Ironside, professor of clinical neuropathology c

a Department of Histopathology, Derriford Hospital, Plymouth PL6 8DH, b Department of Infectious Disease Epidemiology, Faculty of Medicine, Imperial College of Science, Technology and Medicine, London SW7 2AZ, c National CJD Surveillance Unit, University of Edinburgh, Edinburgh EH4 2XU

Correspondence to: D A Hilton david.hilton{at}phnt.swest.nhs.uk

Variant Creutzfeldt-Jakob disease is almost certainly caused by the bovine spongiform encephalopathy agent, and although the disease is rare (115 deaths to date) there is uncertainty about future numbers of cases.1 The lack of a conventional immune response and the inability to detect abnormal prion protein in blood has hampered the development of a blood test.1 Lymphoreticular accumulation of prion protein has been used as a preclinical test for scrapie (the form of the disease in sheep and goats) and is a consistent feature of variant Creutzfeldt-Jakob disease, occurring before the onset of symptoms.2-4 We screened large numbers of specimens from appendicectomies and tonsillectomies for the presence of prion protein in lymphoreticular tissue to determine the number of people with preclinical variant Creutzfeldt-Jakob disease.


    Methods and results
Top
Methods and results
Comment
References

We retrieved appendix and tonsil samples removed between 1995 and 1999 from patients aged 10-50 from histopathology departments across the United Kingdom. The samples were anonymised before testing. We also examined appendix samples removed at autopsy or at surgery from patients with variant Creutzfeldt-Jakob disease. Prion protein was detected by immunohistochemistry with monoclonal antibodies 3F4 (Dako, Ely, Cambridge) and KG9 (Institute for Animal Health, Newbury) and visualised with the catalysed signal amplification system (Dako). We excluded cases with fewer than five secondary lymphoid follicles from the final analyses because in the previously reported case and those examined at autopsy, prion protein was present in around 20% of follicles.4 We tested 11 228 samples, of which 2910 were excluded. Most samples were appendixes and 70% were from patients aged 20-29. In one case we identified prion protein immunoreactivity in a single lymphoid follicle stained with KG9 (figure). The pattern of staining was similar to that seen in the two other patients who developed variant Creutfeldt-Jakob disease (figure1).4 This positive staining was less evident in sections stained with 3F4 antibody. The reason for this discrepancy is not clear but may be due to sampling error because of the focal nature of prion protein deposition. In the appendixes removed before the onset of symptoms in three patients with variant Creutfeldt-Jakob disease, two (removed in 1995 and 1996; see figure) were positive, and the third (removed in 1987) was negative.4 Overall, 19 of 20 appendixes removed at autopsy from cases of variant Creutzfeldt-Jakob disease with adequate numbers of lymphoid follicles had lymphoreticular accumulation of prion protein.




View larger version (283K):
[in this window]
[in a new window]
 
(Left) Distribution of coarse granular prion protein within lymphoid follicle of appendix, suggestive of follicular dendritic cells. (Right) Lymphoreticular accumulation of prion protein in appendix tissue from patient with Creutzfeldt-Jakob disease, removed two years before onset of symptoms



    Comment
Top
Methods and results
Comment
References

One appendix showing the lymphoreticular accumulation of prion protein out of 8318 samples tested gives an estimated detectable prevalence of prion protein accumulation of 120 per million (95% confidence interval, 0.5 to 900) among people aged 10-50 between 1995 and 1999. Our study design precluded transmission studies, but the accumulation of prion protein in lymphoreticular tissue detected by the immunohistochemical technique correlates with the detection of abnormal prion protein by western blotting and remains the only technique shown to reliably predict disease in animals. 2 3 5 The sensitivity and specificity of preclinical lymphoreticular accumulation of prion protein in predicting variant Creutzfeldt-Jakob disease are unknown, but in sheep exposed to scrapie are estimated to be 87% and 94%, respectively.5 At autopsy, 95% of appendixes from patients with variant Creutzfeldt-Jakob disease with adequate amounts of lymphoid tissue showed accumulation of prion protein, as did both appendixes removed during the 1990s from patients who later developed the disease.

We provide the first estimate of the number of people who may be a potential source of variant Creutzfeldt-Jakob disease by iatrogenic spread. Large scale prospective screening of tissue from tonsillectomies is needed to obtain precise data on prevalence. The use of fresh tissue would allow for a semi-automated western blot assay and verification of positive samples by transmission studies. As half of tonsillectomies are in children under 10, who will have had little or no exposure to bovine spongiform encephalopathy, the opportunity for such a study will diminish over time.

    Acknowledgments

We thank histopathology departments and relatives of patients with variant Creutzfeldt-Jakob disease who gave consent for autopsy tissues to be used as positive control material.

Contributors: DAH designed the English study, screened samples tested at Plymouth, and drafted the manuscript; he will act as guarantor for the paper. JWI designed the Scottish study, screened samples tested at Edinburgh, and contributed to the manuscript. ACG performed the statistical analyses and contributed to the manuscript. MP, LC, and PE performed the technical work at Plymouth. LMcC and DR performed the technical work and assisted in screening samples at Edinburgh.

    Footnotes

Funding: Department of Health and the Royal Society. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health.

Competing interests: None declared.


    References
Top
Methods and results
Comment
References

1. Collinge J. Variant Creutzfeldt-Jakob disease. Lancet 1999; 354: 317-323[CrossRef][Web of Science][Medline].
2. Schreuder BEC, van Keulen LJM, Vromans MEW, Langeveld JPM, Smits MA. Preclinical test for prion diseases. Nature 1996; 381: 563[CrossRef][Medline].
3. Hill AF, Butterworth RJ, Joiner S, Jackson G, Rosser MN, Thomas DJ, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion disease with tonsil biopsy samples. Lancet 1999; 353: 183-189[CrossRef][Web of Science][Medline].
4. Hilton DA, Fathers E, Edwards P, Ironside JW, Zajicek J. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet 1998; 352: 703-704[CrossRef][Web of Science][Medline].
5. O'Rourke KI, Baszler TV, Besser TE, Miller JM, Cutlip RC, Wells GAH, et al. Preclinical diagnosis of scrapie by immunohistochemistry of third eyelid lymphoid tissue. J Clin Microbiol 2000; 38: 3254-3259[Abstract/Free Full Text].

(Accepted 30 July 2002)


© BMJ 2002

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Articles

Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study
James W Ironside, Matthew T Bishop, Kelly Connolly, Doha Hegazy, Suzanne Lowrie, Margaret Le Grice, Diane L Ritchie, Linda M McCardle, and David A Hilton
BMJ 2006 332: 1186-1188. [Abstract] [Full Text] [PDF]

Estimate of variant CJD derived from pathology samples
BMJ 2002 325: 0. [Full Text]

Consent for research on stored body samples
BMJ 2002 325: 0. [Full Text] [PDF]

This article has been cited by other articles:

  • Head, M W, Ironside, J W (2007). vCJD and the gut: implications for endoscopy. Gut 56: 9-11 [Full text]  
  • Lourenco, P. C., Schmerr, M. J., MacGregor, I., Will, R. G., Ironside, J. W., Head, M. W. (2006). Application of an immunocapillary electrophoresis assay to the detection of abnormal prion protein in brain, spleen and blood specimens from patients with variant Creutzfeldt-Jakob disease.. J. Gen. Virol. 87: 3119-3124 [Abstract] [Full text]  
  • Ironside, J. W, Bishop, M. T, Connolly, K., Hegazy, D., Lowrie, S., Le Grice, M., Ritchie, D. L, McCardle, L. M, Hilton, D. A (2006). Variant Creutzfeldt-Jakob disease: prion protein genotype analysis of positive appendix tissue samples from a retrospective prevalence study. BMJ 332: 1186-1188 [Abstract] [Full text]  
  • Maher, D. M., Zhang, Z.-Q., Schacker, T. W., Southern, P. J. (2005). Ex Vivo Modeling of Oral HIV Transmission in Human Palatine Tonsil. J. Histochem. Cytochem. 53: 631-642 [Abstract] [Full text]  
  • Clarke, P., Ghani, A. C (2005). Projections of the future course of the primary vCJD epidemic in the UK: inclusion of subclinical infection and the possibility of wider genetic susceptibility. J R Soc Interface 2: 19-31 [Abstract] [Full text]  
  • Norfolk, D R, Glaser, A, Kinsey, S (2005). American fresh frozen plasma for neonates and children. Arch. Dis. Child. 90: 89-91 [Abstract] [Full text]  
  • Lemmer, K., Mielke, M., Pauli, G., Beekes, M. (2004). Decontamination of surgical instruments from prion proteins: in vitro studies on the detachment, destabilization and degradation of PrPSc bound to steel surfaces. J. Gen. Virol. 85: 3805-3816 [Abstract] [Full text]  
  • Marcos, Z., Pffeifer, K., Bodegas, M. E., Sesma, M. P., Guembe, L. (2004). Cellular Prion Protein Is Expressed in a Subset of Neuroendocrine Cells of the Rat Gastrointestinal Tract. J. Histochem. Cytochem. 52: 1357-1365 [Abstract] [Full text]  
  • Hilton, D A, Sutak, J, Smith, M E F, Penney, M, Conyers, L, Edwards, P, McCardle, L, Ritchie, D, Head, M W, Wiley, C A, Ironside, J W (2004). Specificity of lymphoreticular accumulation of prion protein for variant Creutzfeldt-Jakob disease. J. Clin. Pathol. 57: 300-302 [Abstract] [Full text]  
  • Bird, S. M (2004). Recipients of blood or blood products "at vCJD risk". BMJ 328: 118-119 [Full text]  
  • Ghani, A. C (2003). Commentary: Predicting the unpredictable: the future incidence of variant Creutzfeldt-Jakob disease. Int J Epidemiol 32: 792-793 [Full text]  
  • Baier, M., Norley, S., Schultz, J., Burwinkel, M., Schwarz, A., Riemer, C. (2003). Prion diseases: infectious and lethal doses following oral challenge. J. Gen. Virol. 84: 1927-1929 [Abstract] [Full text]  
  • Mabbott, N. A., Young, J., McConnell, I., Bruce, M. E. (2003). Follicular Dendritic Cell Dedifferentiation by Treatment with an Inhibitor of the Lymphotoxin Pathway Dramatically Reduces Scrapie Susceptibility. J. Virol. 77: 6845-6854 [Abstract] [Full text]  
  • Hilton, D A, Ironside, J W (2003). Screening for variant Creutzfeldt-Jakob disease. J. Neurol. Neurosurg. Psychiatry 74: 828-829 [Full text]  
  • Ghani, A. C, Ferguson, N. M, Donnelly, C. A, Anderson, R. M (2003). Short-term projections for variant Creutzfeldt-Jakob disease onsets. Stat Methods Med Res 12: 191-201 [Abstract]  
  • Boelle, P.-y., Thomas, G., Valleron, A.-J., Cesbron, J.-Y., Will, R. (2003). Modelling the epidemic of variant Creutzfeldt-Jakob disease in the UK based on age characteristics: updated, detailed analysis. Stat Methods Med Res 12: 221-233 [Abstract]  
  • Bird, S. M (2003). European Union's rapid TSE testing in adult cattle and sheep: implementation and results in 2001 and 2002. Stat Methods Med Res 12: 261-278 [Abstract]  
  • Budka, H. (2003). Neuropathology of prion diseases. Br Med Bull 66: 121-130 [Abstract] [Full text]  
  • Wadsworth, J. D., Hill, A. F, Beck, J. A, Collinge, J. (2003). Molecular and clinical classification of human prion disease. Br Med Bull 66: 241-254 [Abstract] [Full text]  
  • Will, R. G (2003). Acquired prion disease: iatrogenic CJD, variant CJD, kuru. Br Med Bull 66: 255-265 [Abstract] [Full text]  
  • Dormont, D. (2003). Approaches to prophylaxis and therapy: An investigation into prion disease diversity. Br Med Bull 66: 281-292 [Abstract] [Full text]  
  • Tabrizi, S., Elliott, C., Weissmann, C (2003). Ethical issues in human prion diseases. Br Med Bull 66: 305-316 [Abstract] [Full text]  

Rapid Responses:

Read all Rapid Responses

The use of human tissue in research.
Benjamin Swift
bmj.com, 20 Sep 2002 [Full text]
Is this science ?
Jarlath Hynes
bmj.com, 21 Sep 2002 [Full text]
Goodbye Yellow Brick Road
George A Venters
bmj.com, 26 Sep 2002 [Full text]
Re: The use of human tissue in research.
David A Hilton
bmj.com, 30 Sep 2002 [Full text]
Re: Is this science ?
David A Hilton
bmj.com, 30 Sep 2002 [Full text]
BSE and Acinetobacter
Alan Ebringer
bmj.com, 4 Oct 2002 [Full text]
Questions re. Validity of Test and Sampling
Philip A. Geis
bmj.com, 5 Oct 2002 [Full text]
Re: Questions re. Validity of Test and Sampling
David A Hilton
bmj.com, 7 Oct 2002 [Full text]
Immune activation in peripheral blood of patients with prion diseases
Gabriele Neurauter, et al.
bmj.com, 10 Oct 2002 [Full text]



Doc2Doc Vacancy
Access jobs at BMJ Careers
Whats new online at Student 

BMJ